Osimertinib is used as the first-line therapy for patients with epidermal growth factor receptor
(EGFR)-mutated non-small cell lung cancer (NSCLC). However, early dose reduction is …

Objective. The clinical outcomes of poor performance status (PS) patients with epidermal
growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who are treated …

Osimertinib has become the standard of care for epidermal growth factor receptor (EGFR)-
mutated non-small cell lung cancer (NSCLC). In order to prevent or treat toxicity, the …

Background Response rates of epidermal growth factor receptor (EGFR)-mutated advanced
non-small cell lung cancer (NSCLC) to lower doses of osimertinib [20 mg once daily (OD) …

Background: Non-small cell lung cancer (NSCLC) accounts for about 85% of generally
reported lung cancer patients. Objectives: This is a systematic review of the clinical efficacy …

Osimertinib is a molecularly targeted agent used to treat non-small cell lung cancer
(NSCLC) patients with an epidermal growth factor receptor (EGFR) T790M mutation …

Background: Although the clinical application of osimertinib, a third-generation epidermal
growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been a new step forward in …

Background In the phase 3 FLAURA trial, osimertinib was compared with first-generation
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as a first-line …

Aim Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) approved for patients with EGFR mutated non-small cell lung cancer as …

Introduction The recently published FLAURA trial demonstrated that osimertinib has
remarkable efficacy in front-line setting for non-small cell lung cancer (NSCLC). While this …